Document is current
Any future updates will be listed below
-
Authors
Short, Nicholas J. https://orcid.org/0000-0002-2983-2738
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Macaron, Walid
Jain, Nitin
Haddad, Fadi G. https://orcid.org/0000-0002-9702-8485
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Kadia, Tapan M. https://orcid.org/0000-0002-9892-9832
Kebriaei, Partow
Kugler, Eitan
Matthews, Jairo
Garris, Rebecca
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
Kantarjian, Hagop https://orcid.org/0000-0002-1908-3307
-
Funding
Funding for this research was provided by:
UT | University of Texas MD Anderson Cancer Center (CA016672)
Adaptive Biotechnologies
Amgen
- License Information
-
More Information
Article History
Received: 27 May 2025
Revised: 11 August 2025
Accepted: 15 September 2025
First Online: 21 October 2025
Competing interests
: NJS, EJ, and NJ have received consulting fees and honoraria from Adaptive Biotechnologies. FGH received consulting fees from Amgen. The other authors report no relevant conflicts of interest.
: This study was approved by the Institutional Review Board of MD Anderson Cancer Center (Reference No. PA18-0025) and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board due to the retrospective nature of the study.
